Sir, We appreciate the interest shown by Drs De Ponti and Tonini1 in our study published in the Journal recently.2 We are happy to provide the code number (GW597599) for the NKl receptor antagonist used in the study. Disclosure of this code will make it possible for the readers to search for information on the drug through the usual channels.We also acknowledge that, for the reasons laid out in the letter by Drs De Ponti and Tonini1 early publication of a negative trial in humans has considerable advantages to the scientific community. Journal editors should encourage more of these trials to he published.
展开▼
